Aligos Therapeutics
ALGS
Market cap $23M

7.21 USD

-0.17

2.30%

At close Oct 17, 4:00 PM EDT

1 day

-2.30%

5 days

5.26%

1 month

-49.90%

3 months

-44.02%

6 months

-63.36%

Year to date

-59.36%

1 year

-60.47%

5 years

-98.06%

About: Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Employees: 68

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

0% more funds holding

Funds holding: 49 [Q1] → 49 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

0.64% less ownership

Funds ownership: 63.68% [Q1] → 63.04% (-0.64%) [Q2]

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

63% less capital invested

Capital invested by funds: $45.3M [Q1] → $16.6M (-$28.7M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$75

940%

upside

Avg. target

$75

940%

upside

High target

$75

940%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Ed Arce 46% 1-year accuracy 59 / 128 met price target	940%upside $75	Buy Reiterated	20 Sept 2024
HC Wainwright & Co. Ed Arce 46% 1-year accuracy 59 / 128 met price target	940%upside $75	Buy Initiated	19 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ALGS published over the past 30 days

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 95,000 shares of the Company's stock (the “Inducement Grants”) to newly hired employees on October 8, 2024 (the “Grant Date”), in connection with the commencement of employment. Included in the aggregate number is the grant of an option to purchase 75,000 shares to Dr. Hardean Achneck, in connection with the commencement of his role as Chief Medical Officer.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately.

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Aligos Therapeutics to Present at Investor Conferences in October

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will participate at two investor conferences being webcast in October:

Aligos Therapeutics to Present at Investor Conferences in October

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects.

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT.

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 3,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on September 10, 2024 (the “Grant Date”), in connection with the commencement of employment.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?

Here is how Aligos Therapeutics, Inc. (ALGS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?

Zacks Investment Research

How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

The average of price targets set by Wall Street analysts indicates a potential upside of 648.1% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

Aligos Therapeutics Announces Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company's common stock is expected begin trading on the Nasdaq Capital Market under the same symbol (ALGS) on a split-adjusted basis at the market open on August 19, 2024 with the new CUSIP number 01626L 204.

Aligos Therapeutics Announces Reverse Stock Split

Zacks Investment Research

What Makes Aligos Therapeutics (ALGS) a New Buy Stock

Aligos Therapeutics (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Aligos Therapeutics (ALGS) a New Buy Stock

See News Rankings

Charts implemented using Lightweight Charts™